Abstract:Enterovirus A71 (EV-A71) is an important causative agent of hand-foot-and-mouth disease (HFMD) associated with enormous healthcare and socioeconomic burden. Although a range of studies about EV-A71 pathogenesis have been well described, the underlying molecular mechanism in terms of innate immune response is still not fully understood, especially the roles of TANK-binding kinase 1 (TBK1) and interferon-regulatory factor 3 (IRF3). Here, we applied TBK1 inhibitor and IRF3 agonist, for the first time, to evaluate the antiviral activities of TBK1 and IRF3 in vivo . We found that, through regulating EV-A71-induced type I interferon (IFN) response, IRF3 agonist effectively alleviated EV-A71-induced illness, while TBK1 inhibitor aggravated disease progression. In addition, EV-A71 replication was suppressed in EVA-71-infected mice administrated with IRF3 agonist. On the other hand, more severe pathological alterations of neuronal degeneration, muscle fiber breaks, fractured or fused alveolar walls, and diffuse congestion occurred in EVA-71-infected mice treated with TBK1 inhibitor administration. Furthermore, we determined the concentrations of interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), IL-1β, monocyte chemotactic protein-1 (MCP-1), and IL-10 in both lungs and brains of mice and found that TBK1 inhibitor promoted EV-A71-induced inflammatory response, while IRF3 agonist alleviated it, which was consistent with clinical manifestations and pathological alterations. Collectively, our findings suggest that TBK1 and IRF3 are potential therapeutic targets in EV-A71-induced illness. EV-A71 is an important causative agent of HFMD. There is currently no specific antiviral agent to treat HFMD and the related severe complications. The underlying molecular mechanism controlling host innate immunity after EV-A71 infection is still not fully understood, especially the roles of TBK1 and IRF3. Here, we applied TBK1 inhibitor (TBK1/IKKε-IN-2) and IRF3 agonist (KIN1148) to evaluate the antiviral activities of TBK1 and IRF3 in vivo . We found through regulating EV-A71-induced type I IFN response, IRF3 agonist effectively alleviated EV-A71-induced illness, while TBK1 inhibitor aggravated disease progression. More severe pathological alterations of neuronal degeneration, muscle fiber breaks, fractured or fused alveolar walls and diffuse congestion occurred in EVA-71-infected mice with TBK1 inhibitor treatment, while no obvious pathological change occurred in EVA-71-infected mice with IRF3 agonist treatment and control mice. Furthermore, TBK1 inhibitor promoted EV-A71-induced inflammatory response, while IRF3 agonist alleviated it. Our findings suggest that TBK1 and IRF3 are potential therapeutic targets in EV-A71-induced illness for the development of new antiviral agents and therapeutic strategies.

Potent Inhibition of Human Enterovirus 71 Replication by Type I Interferon Subtypes

Enterovirus 71 Inhibits Cellular Type I Interferon Signaling by Downregulating JAK1 Protein Expression.

Inhibition of EV71 replication by an interferon-stimulated gene product L3HYPDH

Enterovirus 71 inhibits cellular type I interferon signaling by inhibiting host RIG-I ubiquitination

TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases

Enterovirus 71 Suppresses Interferon Responses by Blocking JAK/STAT Signaling through Inducing Karyopherin-α1 Degradation

Enterovirus 71 Suppresses Interferon Responses by Blocking Janus Kinase (jak)/signal Transducer and Activator of Transcription (STAT) Signaling Through Inducing Karyopherin-Α1 Degradation

Inhibition of Enterovirus 71 Replication by an Α-Hydroxy-nitrile Derivative NK-1.9k

Anemoside B4 inhibits enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses

Antiviral activity of the HSP90 inhibitor VER-50589 against enterovirus 71

Characterization of Inflammatory Cytokine Profiles in Cerebrospinal Fluid of Hand, Foot, and Mouth Disease Children with Enterovirus 71-Related Encephalitis in Hangzhou, Zhejiang, China.

Studies on Inhibition of Proliferation of Enterovirus-71 by Compound YZ-LY-0

Ginsenoside Rb1 is an immune-stimulatory agent with antiviral activity against enterovirus 71

Human enterovirus 71 protein interaction network prompts antiviral drug repositioning

Type I Interferon-Induced TMEM106A Blocks Attachment of EV-A71 Virus by Interacting With the Membrane Protein SCARB2

Antiviral drugs (synthetic small molecule inhibitors and nature drugs) against EV71 in enteroviruses: Advances and Perspectives

Differential Regulation of TLR Signaling on the Induction of Antiviral Interferons in Human Intestinal Epithelial Cells Infected with Enterovirus 71.

New Potent EV-A71 Antivirals Targeting Capsid.

Enterovirus 71 antagonizes the antiviral activity of host STAT3 and IL-6R with partial dependence on virus-induced miR-124.

Enterovirus A71 antivirals: Past, present, and future

An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation